VERU INC. Business Acquisition, Pro Forma Revenue
VERU INC. (VERU) reported Business Acquisition, Pro Forma Revenue of $13.66 million for the 12-month period ending 2017-09-30, per its 10-K filed 2018-01-02.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2018-01-02
- VERU INC. business acquisition, pro forma revenue for fiscal 2017 was $13.66M, a 38.33% decline from fiscal 2016.
- VERU INC. business acquisition, pro forma revenue for fiscal 2016 was $22.15M.
| Period end | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|
| 2017-09-30 | $13.66M 10-K · filed 2018-01-02 |
| 2016-09-30 | $22.15M 10-K · filed 2018-01-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |